肿瘤多药耐药的逆转措施

doi:10.3760/cma.j.issn.1673422X.2016.05.011

摘要/Abstract

摘要： 化疗是恶性肿瘤的主要治疗方法，而肿瘤多药耐药（MDR）是导致肿瘤化疗失败的重要原因之一。应用化学药物逆转剂、天然药物（中药）逆转剂、免疫治疗、基因治疗、纳米载体给药系统等逆转肿瘤MDR已取得初步进展。但研制出不良反应小、效果好、能够广泛应用于临床的逆转肿瘤MDR药物，仍需要更大努力。

关键词: 肿瘤, 药物疗法, 多药耐药相关蛋白质类

Abstract: Chemotherapy is one of the main treatment methods in malignant tumor. Tumor multidrug resistance (MDR) is one of the important reasons for the failure of chemotherapy. It makes some progress in reversing tumor MDR, such as chemical drug, traditional Chinese medicine, immunotherapy, gene therapy, nanoparticles drug system and so on. But it takes more effort to develop medicine of less adverse reactions, better pharmacodynamic and application to clinic widely.

Key words: Neoplasms, Drug therapy, Multidrug resistanceassociated proteins

陈颖，张幸平. 肿瘤多药耐药的逆转措施[J]. 国际肿瘤学杂志, 2016, 43(5): 364-367.

Chen Ying, Zhang Xingping. Reversing methods of tumor multidrug resistance[J]. Journal of International Oncology, 2016, 43(5): 364-367.

参考文献

［1］ Palmeira A, Sousa E, Vasconcelos MH, et al. Three decades of Pgp inhibitors: skimming through several generations and scaffolds［J］. Curr Med Chem, 2012, 19(13): 1946-2025. ［2］ Vadlapatla RK, Vadlapudi AD, Pal D, et al. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes［J］. Curr Pharm Des, 2013, 19(40): 7126-7140. ［3］ Wu Q, Yang Z, Nie Y, et al. Multidrug resistance in cancer chemotherapeutics: mechanisms and Lab approaches［J］. Cancer Lett, 2014, 347(2): 159-166. DOI: 10.1016/j.canlet.2014.03.013. ［4］ Saraswathy M, Gong S. Different strategies to overcome multidrug resistance in cancer［J］. Biotechnol Adv, 2013, 31(8): 1397-1407. DOI: 10.1016/j.biotechadv.2013.06.004. ［5］ Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice［J］. Oncologist, 2003, 8(5): 411-424. ［6］ Tiwari AK, Sodani K, Dai CL, et al. Revisiting the ABCs of multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 570-594. ［7］ Tang R, Faussat AM, Perrot JY, et al. Zosuquidar restores drug sensitivity in Pglycoprotein expressing acute myeloid leukemia (AML)［J］. BMC Cancer, 2008, 8(8): 51. DOI: 10.1186/14712407851. ［8］ Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of Pglycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebocontrolled trial of the Eastern Cooperative Oncology Group 3999［J］. Blood, 2010, 116(20): 4077-4085. DOI: 10.1182/blood201004277269. ［9］ Wu CP, Ohnuma S, Ambudkar SV. Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy［J］. Curr Pharm Biotechnol, 2011, 12(4): 609-620. ［10］袁斐, 白钢钢, 苗筠杰, 等. 中药逆转肿瘤细胞多药耐药的研究进展［J］. 中草药, 2014, 45(6): 857-863. DOI: 10.7501/j.issn.02532670.2014.06.023. ［11］ Lu WD, Qin Y, Yang C, et al. Effect of curcumin on human colon cancer multidrug resistance in vitro and in vivo［J］. Clinics (Sao Paulo), 2013, 68(5): 694-701. DOI: 10.6061/clinics/2013(05)18. ［12］ Guo H, Jiang W, Liu W, et al. Extracellular domain of 41BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by antiCD3 x antiPgp bispecific diabody against human multidrugresistant leukemia［J］. Cell Immunol, 2008, 251(2): 102-108. DOI: 10.1016/j.cellimm.2008.04.006. ［13］ Grodzovski I, Lichtenstein M, Galski H, et al. IL2granzyme A chimeric protein overcomes multidrug resistance (MDR) through a caspase 3independent apoptotic pathway［J］. Int J Cancer, 2011, 128(8): 1966-1980. DOI: 10.1002/ijc.25527. ［14］ Mizukoshi E, Nakagawa H, Kitahara M, et al. Phase Ⅰ trial of multidrug resistanceassociated protein 3derived peptide in patients with hepatocellular carcinoma［J］. Cancer Lett, 2015, 369(1): 242-249. DOI: 10.1016/ j.canlet.2015.08.020. ［15］ Mosaffa F, Kalalinia F, Parhiz BH, et al. Tumor necrosis factor alpha induces stronger cytotoxicity in ABCG2overexpressing resistant breast cancer cells compared with their drugsensitive parental line［J］. DNA Cell Biol, 2011, 30(6): 413-418. DOI: 10.1089/dna.2010.1143. ［16］揭惠, 酉明巧, 刘辉, 等. 肿瘤多药耐药的发生机制及逆转策略［J］. 中华中医药学刊, 2013 (7): 1686-1690. ［17］ Binkhathlan Z, Lavasanifar A. Pglycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives［J］. Curr Cancer Drug Targets, 2013, 13(3): 326-346. ［18］ Nieth C, Priebsch A, Stege A, et al. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)［J］. FEBS Lett, 2003, 545(2/3): 144-150. ［19］ Li JM, Zhang W, Su H, et al. Reversal of multidrug resistance in MCF7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acidconjugated polyethylenimine hydroxypropylβcyclodextrin nanocarrier［J］. Int J Nanomedicine, 2015, 10: 3147-3162. DOI: 10.2147/IJN.S67146. ［20］ Tian W, Chen J, He H, et al. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications［J］. Clin Transl Oncol, 2013, 15(5): 335-342. DOI: 10.1007/s1209401209295. ［21］ Hu Y, Xu K, Yagüe E. miR218 targets survivin and regulates resistance to chemotherapeutics in breast cancer［J］. Breast Cancer Res Treat, 2015, 151(2): 269-280. DOI: 10.1007/s1054901533729. ［22］ Milane L, Ganesh S, Shah S, et al. Multimodal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology［J］. J Control Release, 2011, 155(2): 237-247. DOI: 10.1016/j.jconrel.2011.03.032. ［23］ He Q, Shi J. MSN anticancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition［J］. Adv Mater, 2014, 26(3): 391-411. DOI: 10.1002/adma.201303123. ［24］贾晋斌, 韦青燕. 阿霉素脂质体的研究进展［J］. 中国肿瘤, 2011, 20(5): 372-377. DOI: 10.1063/1.3253351. ［25］ Huang C, Li Y, Cao P, et al. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycinresistant SGC7901/ADM gastric cancer cells［J］. J Huazhong Univ Sci Technolog Med Sci, 2011, 31(4): 488-496. DOI: 10.1007/s1159601104780. ［26］ Mao Z, Zhou J, Luan J, et al. Tamoxifen reduces Pgpmediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ERnegative human gastric cancer cells［J］. Biomedicine Pharmacother, 2014, 68(2): 179-183. DOI: 10.1016/j.biopha.2013.10.003.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.